CARDIOMEMS
Device
Abbott Laboratories
Total Payments
$10.1M
Transactions
53,100
Doctors
13,326
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $2.6M | 15,904 | 6,196 |
| 2023 | $3.9M | 19,450 | 6,297 |
| 2022 | $3.6M | 17,746 | 6,387 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $5.2M | 1,378 | 51.3% |
| Food and Beverage | $2.0M | 45,334 | 20.2% |
| Consulting Fee | $1.2M | 1,260 | 12.3% |
| Travel and Lodging | $760,720 | 4,746 | 7.5% |
| Space rental or facility fees (teaching hospital only) | $441,814 | 61 | 4.4% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $301,353 | 113 | 3.0% |
| Compensation for serving as faculty or as a speaker for a medical education program | $122,015 | 127 | 1.2% |
| Education | $9,087 | 73 | 0.1% |
| Debt forgiveness | $4,016 | 8 | 0.0% |
Payments by Type
Research
$5.2M
1,378 transactions
General
$4.9M
51,722 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Hemodynamic-GUIDEd Management of Heart Failure | Abbott Laboratories | $2.4M | 0 |
| Validation of CardioMEMS HF System Cardiac Output Algorithm IDE (VICTOR) | Abbott Laboratories | $1.1M | 0 |
| Examining the Reliability and Validity of the New York Heart Association Classification Guide to Assign Class for Patients with Heart Failure and Application into Practice | Abbott Laboratories | $409,760 | 1 |
| Treatment Of Atrial Fibrillation In Preserved Cardiac Function Heart Failure (TAP-CHF) | Abbott Laboratories | $203,493 | 0 |
| Validation of CardioMEMS HF System Cardiac Output Algorithm IDE | Abbott Laboratories | $135,834 | 0 |
| Temporal Trends of CardioMEMS Utilization and Characteristics of Successful CardioMEMS Programs Within the Veterans Affairs Healthcare System | Abbott Laboratories | $121,400 | 0 |
| Treatment of Atrial Fibrillation in Preserved Cardiac Function Heart Failure (TAP-CHF) | Abbott Laboratories | $115,575 | 0 |
| Examining the Reliability and Validity of the New York Heart Association Classification Guide to Assign Class of Patients with Heart Failure and Application into Practice | Abbott Laboratories | $102,440 | 0 |
| TEAM-HF | Abbott Laboratories | $84,752 | 0 |
| The CardioClip Study: Hemodynamic-Guided Optimization with the CardioMEMS Device of Patients with Heart Failure and Secondary Mitral Regurgitation Undergoing Mitral Transcatheter Edge-to-Edge Repair with the MitraClip Device | Abbott Laboratories | $69,190 | 0 |
| A Phase 4 Sequential Randomized Open Label Multicenter Prospective Comparative Study to Evaluate the Treatment of Atrial Fibrillation in Preserved Cardiac Function Heart Failure (TAP-CHF trial) | Abbott Laboratories | $53,117 | 0 |
| Use of a personalized shared decision-making tool to optimize utilization of pulmonary artery pressure monitoring technology with evidence-based benefits in decreasing hospitalizations for patients with heart failure | Abbott Laboratories | $45,650 | 1 |
| Hemodynamic Monitoring to Prevent Adverse Events Following Cardiogenic Shock Trial (HALO-Shock) | Abbott Laboratories | $32,885 | 0 |
| Use of a Personalized Shared Decision-Making Tool to Optimize Utilization of Pulmonary Artery Pressure Monitoring Technology with Evidence-Based Benefits in Decreasing Hospitalizations for Patients with Heart Failure | Abbott Laboratories | $30,000 | 0 |
| Cardiac Resynchronization Heart Failure Follow Up Clinic | Abbott Laboratories | $28,000 | 0 |
| Temporal Trends of CardioMEMs Utilization and Characteristics of Successful CardioMEMs Programs within the Veterans Affairs Healthcare System | Abbott Laboratories | $26,000 | 0 |
| Hemodynamic-GUIDEd Management of Heart Failure (GUIDE-HF) | Abbott Laboratories | $24,426 | 0 |
| Risk Stratification for Left Ventricular Assist Device | Abbott Laboratories | $21,840 | 0 |
| Temporal Trends of CardioMEMs: Utilization and Characteristics of Successful CardioMEMS Programs Within the Veterans Affairs Healthcare System | Abbott Laboratories | $20,000 | 1 |
| Temporal Trends of CardioMEMs: Utilization and Characteristics of Successful CardioMEMs Programs within the Veterans Affairs Healthcare System | Abbott Laboratories | $20,000 | 0 |
Top Doctors Receiving Payments for CARDIOMEMS
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Edison, NJ | $5.7M | 1,508 |
| , C.N.S | Clinical Nurse Specialist | Urbana, IL | $153,815 | 2 |
| , M.D | Cardiovascular Disease | Columbia, SC | $98,379 | 239 |
| , DO | Advanced Heart Failure and Transplant Cardiology | Omaha, NE | $81,442 | 213 |
| , M.D | Cardiovascular Disease | Roslyn, NY | $78,997 | 143 |
| , MD | Advanced Heart Failure and Transplant Cardiology | Saint Paul, MN | $56,208 | 110 |
| , APNP | Registered Nurse | Milwaukee, WI | $48,164 | 153 |
| , MD | Internal Medicine | Lees Summit, MO | $46,219 | 15 |
| , M.D., PH.D | Cardiovascular Disease | Minneapolis, MN | $44,303 | 108 |
| , M.D | Cardiovascular Disease | Portland, OR | $42,194 | 130 |
| , MD | Cardiovascular Disease | Winchester, VA | $42,110 | 144 |
| , M.D. PH.D | Cardiovascular Disease | Minneapolis, MN | $41,302 | 88 |
| , MD | Cardiovascular Disease | Austin, TX | $38,968 | 208 |
| , MD | Advanced Heart Failure and Transplant Cardiology | Austin, TX | $37,636 | 129 |
| , MD | Interventional Cardiology | Westerly, RI | $29,716 | 102 |
| , M.D | Internal Medicine | Houston, TX | $28,625 | 16 |
| , PA | Physician Assistant | Rochester, MN | $28,271 | 136 |
| Wayne Levy | Cardiovascular Disease | Seattle, WA | $27,500 | 18 |
| , FNPC | Nurse Practitioner | Wausau, WI | $26,904 | 112 |
| , M.D | Cardiovascular Disease | San Diego, CA | $26,762 | 59 |
| , MD | Cardiovascular Disease | New Haven, CT | $26,350 | 70 |
| , MD | Cardiovascular Disease | Oklahoma City, OK | $24,388 | 60 |
| , MD | Otolaryngology/Facial Plastic Surgery | Baltimore, MD | $24,197 | 4 |
| , M.D | Clinical Cardiac Electrophysiology | New York, NY | $22,914 | 43 |
| , MD, MS | Internal Medicine | San Francisco, CA | $21,573 | 53 |
Ad
Manufacturing Companies
- Abbott Laboratories $10.1M
Product Information
- Type Device
- Total Payments $10.1M
- Total Doctors 13,326
- Transactions 53,100
About CARDIOMEMS
CARDIOMEMS is a device associated with $10.1M in payments to 13,326 healthcare providers, recorded across 53,100 transactions in the CMS Open Payments database. The primary manufacturer is Abbott Laboratories.
Payment data is available from 2022 to 2024. In 2024, $2.6M was paid across 15,904 transactions to 6,196 doctors.
The most common payment nature for CARDIOMEMS is "Unspecified" ($5.2M, 51.3% of total).
CARDIOMEMS is associated with 20 research studies, including "Hemodynamic-GUIDEd Management of Heart Failure" ($2.4M).